Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $11 at Goldman Sachs, 'Zoryve launches trending positively'
February 28, 2024 3:31 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $11.00 (from $6.00) while maintaining a Neutral rating.
The analyst comments "ARQT reported 4Q23 results with net Zoryve (roflumilast cream) sales in plaque psoriasis of $13.5mn, above our and Visible Alpha Consensus estimates of... More
